Literature DB >> 27323876

Screening: A risk-based framework to decide who benefits from screening.

Philip E Castle1, Hormuzd A Katki2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27323876      PMCID： PMC5505517          DOI： 10.1038/nrclinonc.2016.101

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  12 in total

Review 1.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

2.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  CA Cancer J Clin       Date:  2012-03-14       Impact factor: 508.702

3.  Radical prostatectomy versus observation for localized prostate cancer.

Authors:  Timothy J Wilt; Michael K Brawer; Karen M Jones; Michael J Barry; William J Aronson; Steven Fox; Jeffrey R Gingrich; John T Wei; Patricia Gilhooly; B Mayer Grob; Imad Nsouli; Padmini Iyer; Ruben Cartagena; Glenn Snider; Claus Roehrborn; Roohollah Sharifi; William Blank; Parikshit Pandya; Gerald L Andriole; Daniel Culkin; Thomas Wheeler
Journal:  N Engl J Med       Date:  2012-07-19       Impact factor: 91.245

4.  Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.

Authors:  Joshua A Roth; Roman Gulati; John L Gore; Matthew R Cooperberg; Ruth Etzioni
Journal:  JAMA Oncol       Date:  2016-07-01       Impact factor: 31.777

Review 5.  From differences in means between cases and controls to risk stratification: a business plan for biomarker development.

Authors:  Nicolas Wentzensen; Sholom Wacholder
Journal:  Cancer Discov       Date:  2013-01-08       Impact factor: 39.397

6.  Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.

Authors:  Hormuzd A Katki; Stephanie A Kovalchik; Christine D Berg; Li C Cheung; Anil K Chaturvedi
Journal:  JAMA       Date:  2016-06-07       Impact factor: 56.272

7.  Risk assessment to guide the prevention of cervical cancer.

Authors:  Philip E Castle; Mario Sideri; Jose Jeronimo; Diane Solomon; Mark Schiffman
Journal:  J Low Genit Tract Dis       Date:  2008-01       Impact factor: 1.925

8.  Targeting of low-dose CT screening according to the risk of lung-cancer death.

Authors:  Anil K Chaturvedi; Hormuzd A Katki; Stephanie A Kovalchik; Martin Tammemagi; Christine D Berg; Neil E Caporaso; Tom L Riley; Mary Korch; Gerard A Silvestri
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

Review 9.  Population-based screening for cancer: hope and hype.

Authors:  Yiwey Shieh; Martin Eklund; George F Sawaya; William C Black; Barnett S Kramer; Laura J Esserman
Journal:  Nat Rev Clin Oncol       Date:  2016-04-13       Impact factor: 66.675

10.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.

Authors:  Guglielmo Ronco; Joakim Dillner; K Miriam Elfström; Sara Tunesi; Peter J F Snijders; Marc Arbyn; Henry Kitchener; Nereo Segnan; Clare Gilham; Paolo Giorgi-Rossi; Johannes Berkhof; Julian Peto; Chris J L M Meijer
Journal:  Lancet       Date:  2013-11-03       Impact factor: 79.321
View more
  5 in total

1.  Quantifying risk stratification provided by diagnostic tests and risk predictions: Comparison to AUC and decision curve analysis.

Authors:  Hormuzd A Katki
Journal:  Stat Med       Date:  2019-04-30       Impact factor: 2.373

2.  Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.

Authors:  Vidit N Munshi; Rebecca B Perkins; Stephen Sy; Jane J Kim
Journal:  Am J Obstet Gynecol       Date:  2021-09-20       Impact factor: 10.693

3.  Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis.

Authors:  Megan A Clarke; Beverly J Long; Arena Del Mar Morillo; Marc Arbyn; Jamie N Bakkum-Gamez; Nicolas Wentzensen
Journal:  JAMA Intern Med       Date:  2018-09-01       Impact factor: 21.873

4.  A novel metric that quantifies risk stratification for evaluating diagnostic tests: The example of evaluating cervical-cancer screening tests across populations.

Authors:  Hormuzd A Katki; Mark Schiffman
Journal:  Prev Med       Date:  2018-02-14       Impact factor: 4.018

5.  A community jury study exploring the public acceptability of using risk stratification to determine eligibility for cancer screening.

Authors:  Rebecca A Dennison; Rachel A Boscott; Rae Thomas; Simon J Griffin; Hannah Harrison; Stephen D John; Sowmiya A Moorthie; Stephen Morris; Sabrina H Rossi; Grant D Stewart; Chloe V Thomas; Juliet A Usher-Smith
Journal:  Health Expect       Date:  2022-05-08       Impact factor: 3.318
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.